Click Here
Pharmaceutical Technology E-Alert:
Having trouble viewing this e-mail? Click here.
You are subscribed to %%list.name%% as %%emailaddr%%.
Unsubscribe from this list.
  Pharmaceutical Technology Europe E-Alert
 
JUNE 19, 2009
IN THIS ISSUE
EMEA survey
Cross-border directive
Action on rare diseases
PTE on Twitter
More...

Click Here

EMEA seeks your opinion
Following changes to European legislation, the European Medicines Agency (EMEA) will make public some of the information in EudraCT — a database that contains information on clinical trials in Europe. More...

Controversial EU cross-border directive
Draft legislation that would allow patients to seek treatment in any EU country was attacked at the annual congress of the European Federation of Public Services Union (EPSU), which urged EU health ministers to redraft the proposal so that its legal basis encompasses public health and not just the internal market. More...

Europe takes action on rare diseases
Stakeholders say that Europe and its rare disease patients will benefit from a series of political commitments that Health Ministers from all 27 member states have signed up to by adopting a Council Recommendation on European Action in the Field of Rare Diseases. More...

Tweet tweet!
Follow Pharmaceutical Technology Europe on Twitter! More...

Eli Lilly faces lawsuits for illegal marketing
Eli Lilly urged doctors to prescribe Zyprexa for elderly dementia patients despite having evidence that the medicine was not effective for those patients, says a report by Bloomberg. More...

Renvela approved for chronic kidney disease
The European Commission has approved Genzyme Corp's Renvela for patients with chronic kidney disease (CKD). The approval covers both tablet and powder formulations. More...

Key Topic Updates
July events
8th International Bio Forum & Bio Expo Japan (Japan)
The Scale-Up of Chemical Processes (Canada)
ISSCR 7th Annual Meeting (Spain)
Submit your event
 
Latest articles
Improving liposome integrity and easing bottlenecks to production
Formulation effects on the thermomechanical properties and permeability of free films and coating films
Where have we reached with REACH?
More latest articles
 
The UK bio industry on its knees?
Forecasted growth for the 2009 global pharmaceutical market
Master data management solutions
More online exclusives

Key Topic Updates

Survey
Do you use professional webcasts as a source of information/education?
  Yes 65%
  No 15%
  Not yet, but I would if they were of specific interest 20%

This week we would like to know...

A new law would give Europeans the right to seek healthcare abroad more easily. Does this risk putting medical tourism before universal access to quality domestic healthcare?
Click here to vote

Contact Us
Click here to contact editorial.

Click here to contact sales.


You are subscribed to %%list.name%% as %%emailaddr%%. To unsubscribe from this list click here.

To ensure delivery to your Inbox, please add %%email.list%% to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.